XML 89 R31.htm IDEA: XBRL DOCUMENT v3.25.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Research and Development Cost $ 2,143,471 $ 1,496,129
Depreciation expense 156,002 18,098
Unbilled receivables 1,653,007 1,494,553
Revenue receive as consideration $ 812,000  
Short term lease term 12 months  
Costs and expenses $ 68,000  
Contract costs 136,651  
Cash and cash equivalents 10,651,644 10,445,404
Inventory allowance 50,000 0
Revenues 445,445 743,952
Contract loss provision $ 1,000,000 500,000
Share based description cumulative adjustment of approximately $55,000 in the quarter ended December 31, 2023 to reduce its forfeiture rate estimate to approximately 5% of the total stock-based compensation recognized during the year  
Treatability study services [Member]    
Revenues $ 217,489 88,134
AirSCWO [Member]    
Revenues $ 227,956 $ 655,818
Warrants [Member]    
Antidilutive Excluded from Computation of Earnings Per Share, Amount 14,675,244 1,235,000
Unvested Restricted Stock [Member]    
Antidilutive Excluded from Computation of Earnings Per Share, Amount 3,549,292  
Options [Member]    
Antidilutive Excluded from Computation of Earnings Per Share, Amount 15,843,116 10,828,174
Two Customer [Member] | Revenue [Member]    
Concentrations of Credit Risk 72.00%  
Concentrations of Credit Risk (72.00%)  
One Customer [Member] | Revenue [Member]    
Unbilled receivables $ 1,653,007 $ 1,485,803
Concentrations of Credit Risk 88.00%  
Concentrations of Credit Risk (88.00%)  
One Customer [Member] | Accounts Receivable [Member]    
Concentrations of Credit Risk   51.00%
Concentrations of Credit Risk   (51.00%)
Three Customer [Member] | Accounts Receivable [Member]    
Concentrations of Credit Risk 89.00%  
Concentrations of Credit Risk (89.00%)